《国际循环》：刚刚结束的ESC2014科学年会有哪些亮点？本届ESC & GWICC联合论坛将重点向中国医生传递哪些重要信息？

　　International Circulation: What do you think were the main highlights of the ESC2014 scientific annual meeting? What take-home messages will the current ESC & GWICC Joint Forum offer participants?

　　Vardas教授：今年在巴塞罗那我们举办了一届成功的大会，并在大会上发布了5个最新ESC指南。这些指南都是最新制定的重要指南，给我们传递了很多信息。例如，肥厚型心肌病指南中创建了一种评估心源性猝死风险以及未来是否需要植入ICD的新计算工具。肥厚型心肌病新指南中的风险评估采用了这样一种新方法。此外，ESC 2014年会还发布了很多重要临床试验如有关心力衰竭的PARADIGH试验的结果。PARADIGH试验结果显示，新药物LCZ696能够显著降低心力衰竭患者的发病率及死亡率。另一项在心力衰竭患者中开展的CONFIRM试验则提示，心力衰竭患者需要补铁。简而言之，这些都是ESC 2014年会的一些关键信息。

　　Dr Vardas: In Barcelona this year， we had a very successful Congress. We had the opportunity there to present five new European Society of Cardiology guidelines. The guidelines are new and important and bear a number of messages. For example， in the guidelines for hypertrophic cardiomyopathy， we have developed a new calculator for determining the possibility of sudden cardiac death and the consequent need or not for ICD implantation. The estimation of the risk in the new guidelines for hypertrophic cardiomyopathy is derived from a new basis. Also at the Congress， we had the opportunity to listen to the results of some very important trials， like the PARADIGM trial in heart failure. It seems a new drug， which is a combination of drugs， reduces the morbidity and mortality in patients with heart failure very significantly. Another trial， the CONFIRM trial， again in patients with heart failure， indicates the need for iron supplementation. So briefly， these are some of the key messages coming from the recent Congress.